PhRMA welcomes US Congressional support for Pediatric Reauthorization ACT
US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) has welcomed the bipartisan support for the BPCA and PREA Reauthorization Act of 2012 in the House of Representatives and for the Senate’s Better Pharmaceuticals and Devices for Children Act of 2012, both of which would permanently reauthorize the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA).
David Wheadon, PhRMA senior vice president for scientific and regulatory Affairs, commented: “BPCA and PREA have been exceedingly successful in improving medical care for children by driving research to create innovative medicines for use in pediatric patients. Prior to their passage, roughly 70 percent of medicines taken by children lacked pediatric dosing information. As of 2008, thanks to BPCA and PREA, between 50% and 60% of medicines have been studied in some part of the pediatric population.”
Will provide certainty for pediatric studies
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze